SightfileU.S. market data from official filings

ORGANOGENESIS HLDGS INC (ORGO)

Name: ORGANOGENESIS HLDGS INC (ORGO) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001661181 · EDGAR filings · Updated 2026-06-16

ORGANOGENESIS HLDGS INC (ORGO) has reported institutional ownership of 48.0%, with 121 institutional managers holding positions valued at $146.7M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings, triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).

Institutional ownership

48.0%

Institutional managers

121

Reported 13F value

$146.7M

Insider activity

86 trans.

−$838.1K net selling

Data flags

3 active

from SEC filings

Latest updates

2026-06-16 — Current report (8-K) filed
2026-05-07 — Quarterly report (10-Q) filed
2026-05-07 — Current report (8-K) filed
2026-04-30 — ARS filed
2026-04-30 — Proxy statement (DEF 14A) filed
2026-04-24 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ORGANOGENESIS HLDGS INC has 121 institutional holders and institutional ownership of 48.0%.

Insider activity

Insiders reported 86 transactions (7 buys, 6 sells) across 16 reporting insiders, with a net reported value of −$838.1K.

Data flags from SEC filings

Active triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04), most recently filed 2024-11-13 (recurring since 2024-11-13) — source filing. The authoritative details are those stated in the filing itself.

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2021-08-09 (recurring since 2020-03-09) — source filing. The authoritative details are those stated in the filing itself.

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2021-05-27 (recurring since 2021-05-27) — source filing. The authoritative details are those stated in the filing itself.

Related companies

EUPRAXIA PHARMACEUTICALS INC (EPRX) · IMMUNEERING CORP (IMRX) · DELCATH SYS INC (DCTH) · KORRO BIO INC (KRRO) · CVRX INC (CVRX) · NEUMORA THERAPEUTICS INC. (NMRA)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-16.